Roche's Giredestrant Combo Nearly Doubles PFS in Advanced Breast Cancer; FDA Accepts NDA
RHHBY sits 30% above its 52-week low of $40.05.
Summary
Genentech's giredestrant plus everolimus significantly improved progression-free survival in ER-positive advanced breast cancer, with median PFS of 10.0 vs 5.5 months in ESR1-mutated patients (HR=0.38) and 8.8 vs 5.5 months in the ITT population (HR=0.56). The FDA accepted the NDA for this combination with a PDUFA date of December 18, 2026, and also accepted a Priority Review NDA for adjuvant giredestrant with a PDUFA date of November 30, 2026. This is the first positive Phase III readout for giredestrant and positions it as a potential new standard in post-CDK4/6 inhibitor breast cancer. The data were published in NEJM, adding credibility. Watch for FDA decisions in late 2026.
At the time of this announcement, RHHBY was trading at $51.88 on OTC in the Life Sciences sector, with a market capitalization of approximately $334.9B. The 52-week trading range was $40.05 to $60.85. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.